Rifaximin
Brand names: Xifaxan
At a glance
- Medicare prescriptions, 2024
- 275,401
- Medicare drug cost
- $757.7M
- Average cost per prescription
- $2,751
- Clinicians who prescribed it
- 10,255
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
To reduce the development of drug-resistant bacteria and maintain the effectiveness of XIFAXAN and other antibacterial drugs, XIFAXAN when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. XIFAXAN is a rifamycin antibacterial indicated for: • Treatment of travelers’ diarrhea (TD) caused by noninvasive strains of Escherichia coli in adult and pediatric patients 12 years of age and older. • Reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults. • Treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults. Limitations of Use TD: Should not use in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than Escherichia coli. 1.1 Travelers’
From the FDA-approved prescribing information (label dated June 2025). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Gastroenterology 28.5%
- Nurse Practitioners 19.8%
- Internal Medicine 16.0%
- Family Medicine 11.6%
- Physician Assistants 11.0%
- Hepatology 7.8%
- Geriatric Medicine 1.8%
- Hospitalist 0.8%
- General Practice 0.5%
- Infectious Disease 0.3%
- Hospice & Palliative Medicine 0.3%
- Nephrology (Kidney) 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 14% from 2019 to 2024.
Biggest change by state since 2019
- Kentucky +52%
- South Carolina +51%
- Virginia +41%
- Michigan +34%
- Arizona +30%
- New Jersey (smallest change) −5%
- Florida (smallest change) −1%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
A-S Medication Solutions
| Strength | Looks like | Imprint |
|---|---|---|
| 200 mg | pink round tablet, 10 mm | SX |
Avera Mckennan Hospital
| Strength | Looks like | Imprint |
|---|---|---|
| 200 mg | pink round tablet, 10 mm | SX |
Cardinal Health 107, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 550 mg | pink oval tablet, 19 mm | RFX |
Carilion Materials Management
| Strength | Looks like | Imprint |
|---|---|---|
| 200 mg | pink round tablet, 10 mm | SX |
Salix Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 200 mg | pink round tablet, 10 mm | SX |
| 550 mg | pink oval tablet, 19 mm | RFX |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
Drug makers reported $3.1M in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Salix Pharmaceuticals, A Division of Bausch Health US, LLC $3.1M
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.